TLRY 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围

03
价格 $3.61
市值 (MRQ) $475M
P/E (TTM) -3.3
EPS (TTM) $-1.09
收入 (TTM) $915M
ROE (TTM) -7.8%
负债/权益 0.0
52周区间 $1–$16

TLRY 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图

04
区间
条形图

柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。

股票拆分 1
除息日 拆股 类型
2025年12月2日 1-for-10 反向

关于 Tilray Brands, Inc. - Common Stock 公司概况(来自维基百科)

05 · wikidata

Tilray Brands, Inc. is an American pharmaceutical, cannabis-lifestyle and consumer packaged goods company, incorporated in the United States, headquartered in New York City. Tilray also has operations in Canada, Australia, New Zealand,Latin America, with growing facilities in Germany, Portugal and the United Kingdom.

In December 2020, the company announced a merger with Aphria, and now operates under the Tilray name and its ticker symbol on NASDAQ and the Toronto Stock Exchange.

Tilray also owns several breweries and was ranked by the Brewers Association as the 4th largest craft beer company in the US in 2025.

History

Founded in 2013, Tilray was originally incorporated under the umbrella of Seattle-based Privateer Holdings and was one of Canada's first licensed producers. At the end of 2014, it secured the first institutional investment in the cannabis industry from Founders Fund, a San Francisco-based venture capital fund. In 2016, it became the first cannabis company to conduct a clinical trial approved by Health Canada. The trial evaluated the therapeutic potential of medical cannabis. In January 2017, Tilray was certified for good manufacturing practices.

By October 2018, the company had raised $1.1 billion. In July 2018, it became the first cannabis company to trade publicly on a major U.S. stock exchange, opening on the NASDAQ exchange at a price of $17 per share, which increased in September 2018 to $214 per share, and then descended to $29 per share by August 2019. The IPO raised US$153 million.

In September 2018, Tilray became the first Canadian cannabis company to legally export medical cannabis to the U.S. for a clinical trial. In December 2018, the company signed a deal with Novartis subsidiary Sandoz to sell, distribute and co-brand Tilray's non-smokeable/non-combustible medical cannabis products in legal markets worldwide. On June 19, 2018, Tilray announced the launch of High Park Company which operates in the adult recreational cannabis market to establish unique adult-use brands in Canada.

Since September 2022, Tilray has been licensed by the Polish and Italian Ministries of Health to import and distribute THC25 medical cannabis throughout Poland and Italy.

In August 2023, Tilray acquired eight beverage brands in addition to the breweries of the brands from Anheuser-Busch for $85 million.

Strategic partnerships and acquisitions

In 2018, Tilray announced it had entered into global alliance with Sandoz, a division of Novartis to co-brand and distribute non-combustible medical cannabis products in global markets where it is legally authorized. The Globe and Mail dubbed this partnership as ‘big-pharma’s first foray into cannabis’.

Also in 2018, Tilray announced a $100-million joint venture with the world's largest brewer, AB InBev to research non-alcohol tetrahydrocannabinol (THC) and cannabidiol (CBD)-infused beverages, through their respective subsidiaries, Labatt Breweries and High Park Company.

In 2019, Tilray signed a $250 million revenue-sharing deal with U.S. based brand company, Authentic Brands Group, to leverage ABG brand names, such as Juicy Couture, Greg Norman, and Nine West to create cannabis products. ABG has a portfolio of over 50 brands.

In February 2019, Tilray acquired Manitoba Harvest, a hemp foods manufacturer, for $317 million from Compass Diversified Holdings. The acquisition allowed Tilray to use Manitoba Harvest's retail distribution network to enter the U.S. CBD market. Manitoba Harvest's products are available in approximately 13,000 U.S. stores and 3,600 in Canada.

Also in 2019, Tilray entered into an agreement with Natura Naturals Holdings which owns 155,000 square feet of licensed cultivation greenhouses in Leamington, Ontario. The acquisition doubled the cultivation ability of the company in Canada. In May 2020, Tilray announced closure of the High Park Gardens site (previously Natura Naturals) for cost reductions.

In July 2019, Tilray acquired U.K.-based Smith & Sinclair to develop CBD-infused edibles. In August 2019, Tilray acquired Alberta cannabis retailer, Four20.

On April 10, 2023, Tilray announced an agreement to acquire Hexo Corp. for approximately US$56 million. Hexo shareholders will receive 0.4352 of a share of Tilray common stock in exchange for each share held.

On March 2 2026, Tilray announced a £33m ($44.5 million) deal to acquire British brewer BrewDog's global brand, intellectual property, U.K. brewing facilities, and a network of pubs across the U.K. and Ireland. The deal covers BrewDog's core identity and physical footprint in the U.K., which includes brewing operations and 11 pubs.

Merger with Aphria

On 15 December 2020, Aphria conducted a reverse acquisition of Tilray, creating the largest global cannabis company by revenue and geographic reach. The chief executive officer (CEO) of Aphria, Irwin D. Simon, stated that the merger strategy was to capture Tilray's business assets and public trading exposure in the United States and its free trade abilities in Europe, enabling potential for becoming a global operation. Irwin was named as CEO and chairman of the board for the merged company, and Tilray CEO, Brendan Kennedy, will be a member of the board of directors. The merged companies will keep Tilray's name and trade under the Tilray ticker symbol, TLRY, on the NASDAQ exchange.

By combining assets, the new Tilray company will develop craft beer and cannabis-infused beverages in partnership with Anheuser-Busch InBev, and have branded hemp and cannabidiol products. According to one source, the world market potential for cannabis products is $94 billion by 2025.

Brewery ownership

Tilray also owns several breweries: Montauk Brewing Company, Good Supply Beer, 10 Barrel Brewing Company, Square Mile Cider Company, Terrapin Beer Company, Truss Beverage Co and BrewDog breweries. Tilray's beer division ranked No. 9 on the Brewers Association's annual report of the US nation's top craft companies based on beer sales volume in 2022.

Alpine Beer Company

Founded in 1999 in Alpine, California, the Alpine Beer Company produced award-winning sour beers. The company would be acquired by the Green Flash Brewing Company in 2014 and continued existence as a brand.

Blue Point Brewing Company

Founded in a former ice factory in 1998 to fill the niche of a Long Island focused Microbrewery. The company's flagship "Toasted Lager" won a gold medal at the 2006 World Beer Cup in the American-Style Amber Lager category. The company distributed their beer to 19 states and Washington D.C. before being purchased by Anheuser-Busch InBev on February 5, 2014, for nearly $24 million. Citing financial shortfall in part due to the 2023 Bud Light boycott, Anheuser-Busch sold the brand to Tilray in August 2023.

Breckenridge Brewery

Founded in Breckenridge, Colorado in 1990 as the state's third craft brewery before moving most of their production to Denver in 1992. In 2010 the company merged with the Wynkoop Brewing Company and purchased the Phantom Canyon Brewing company to become the Breckenridge-Wynkoop LLC. In 2015 they moved to a new facility in Littleton, Colorado and was producing 70,000 barrels of beer per year. On December 22, 2015, Anheuser-Busch InBev announced its intent to purchase just Breckenridge Brewery from Breckenridge-Wynkoop LLC, splitting the companies with the purchase finalizing in 2016. Anheuser-Busch sold the brand to Tilray in August 2023.

Green Flash Brewing Company

Founded in 2002 in Vista, California before moving to San Diego in 2011. The company operated a 44,000 barrel per year facility in San Diego in 2011, and a 100,000 barrel per year facility in Virginia Beach, Virginia in 2013. By 2014 their beer was being sold in all 50 states, as well as internationally and they purchased the Alpine Beer Company. The company peaked in 2016 when it was the 37th largest producer of beer in the United States, afterwards the company began a rapid decline due to the rise of rival craft beer producers. In 2018 they cut distribution internationally and to 42 states and laid off 15% of their workforce and defaulted on their loans to construct the Virginia Beach facility. The company would be sold to a group of private investors by the end of the year, who would sell the company to Tilray in 2020.

Redhook Ale Brewery

Founded in Seattle in 1981, Redhook specializes in the production of India pale ales. A founding member of the Craft Brew Alliance, the company's distribution rights were bought by Cisco Brewers in 2018. In 2019 the Craft Brew Alliance, and its properties, were acquired by Anheuser-Busch InBev with Redhook operating as a brand. Anheuser-Busch sold the brand to Tilray in August 2023.

Shock Top

A Belgian-Style, spiced Witbeer brand introduced as a seasonal beer by Anheuser-Busch in February 2006, however, the beer's popularity quickly grew and was used as a rival to Molson Coors' Blue Moon. The brand entered a decline following a failed rebranding effort in 2017 and, citing financial shortfall in part due to the 2023 Bud Light boycott, Anheuser-Busch sold the brand to Tilray in August 2023.

SweetWater Brewing Company

A craft brewery founded in 1997 by Freddy Bensch and Kevin McNerney in Atlanta, Georgia. SweetWater's beers are unpasteurized and distribution is limited to select states. SweetWater would be acquired by Aphria In November 2020 for $300 million. Later, in December 2020, Aphria merged with Tilray bringing SweetWater under Tilray's ownership.

Widmer Brothers Brewery

Founded in 1984 in Portland, Oregon, the company primarily produced Hefeweizen. In 2007 Widmer and Redhook announced that they were going to merge to form the Craft Brewers Alliance, which was renamed to the Craft Brew Alliance in 2012. The goal of which was to offer smaller regional beers a national distribution network. In 2019 Widmer and the whole of the Craft Brew Alliance was bought by Anheuser-Busch InBev, with Widmer operating as a brand. Anheuser-Busch sold the brand to Tilray in August 2023.

Food and drink

HiBall Energy

HiBall Energy was founded in 2005 by Todd Berardi and was based out of San Francisco. They produced organic energy drinks and were purchased by Anheuser-Busch on July 20, 2017, in an effort to diversify into non-alcoholic beverages. Their products were low in sugar, produced with fair-trade ingredients, and were available at 14,000 locations prior to its acquisition by Anheuser-Busch. On May 19, 2023, Anheuser-Busch announced that they were discontinuing HiBall alongside their box wine brand Babe Wine, stating that they will be focusing on their "mega brands" instead. This came despite HiBall having a dedicated consumer fan-base that heavily protested the discontinuation. An Anheuser-Busch spokesmen stated that the discontinuation had nothing to do with the 2023 Bud Light boycott. Anheuser-Busch sold the HiBall brand to Tilray alongside seven of their beer brands in August 2023.

Preliminary clinical research

In partnership with University of Sydney, NSW Government, Chris O'Brien Lifehouse, Tilray participated in a clinical trial testing the efficacy and tolerability of medical cannabis as a possible treatment for the side effects of chemotherapy. Led by The Hospital for Sick Children, in Toronto, Canada, Tilray provided a cannabidiol (CBD) oil product available in Canada to test the efficacy and tolerability of medical cannabis oil as a possible treatment for pediatric epilepsy (Dravet syndrome). In partnership with the University of British Columbia, Tilray provided medical cannabis products used to test medical cannabis as a possible treatment for post-traumatic stress disorder. In partnership with the Grupo Español de Investigación en Neurooncología GEINO, in Spain, Tilray supplied medical cannabis products for the trial testing the efficacy and tolerability of medical cannabis as a possible treatment for glioblastoma.

In 2019, Tilray signed an agreement with Cannamedical Pharma GmbH to export $3.3 million worth of medical cannabis from its Portugal facility to Germany, marking Tilray's first export from Tilray Portugal Unipessoal, Lda. Tilray also has a research partnership with Coimbra University in Portugal.

In August 2019, Tilray announced a partnership with New York University to study the potential ability of CBD to treat alcohol use disorder and post-traumatic stress disorder. In partnership with New York University, Tilray supplied CBD for a clinical trial studying its possible efficacy for treating disorders caused by breast cancer treatments.

来源:维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗

Wikidata ↗

行业板块Healthcare 行业Pharmaceuticals 员工3595 国家CA

10年表现 收入、净利润、利润率和每股收益趋势

06
收入$915M
2021-05-31 → 2026-05-31
EPS$-1.09
2021-05-31 → 2026-05-31
自由现金流·
2021-05-31 → 2025-05-31
净利率-13.3%
2021-05-31 → 2026-05-31
估值与比率 07–12

估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜?

指标 5年趋势 TLRY 5年均值 同行中位数 结论
P/E (TTM) -3.35年均值 ≈-3.6 ≈-3.6 · ·
P/S (TTM) 0.55年均值 ≈1.1 ≈1.1 · ·
市净率 (MRQ) 0.35年均值 ≈0.4 ≈0.4 · ·
EV / EBITDA (企业价值 / EBITDA) -4.05年均值 ≈-5.1 ≈-5.1 · ·
Price / Cash Flow (市现率) -6.95年均值 ≈-21.3 ≈-21.3 · ·
EV / Revenue (市值/营收) 0.35年均值 ≈0.8 ≈0.8 · ·
市净率(有形资产) (MRQ) 0.35年均值 ≈1.5 ≈1.5 · ·

同行中位数按每项指标的标准化基础计算,可能与本股票显示的TTM/MRQ基础不完全匹配。

价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判

收益历史 每股收益实际值 vs 预估值,惊喜%,达标率,下次财报日期

14
平均惊喜 -1438.0%
下次报告 十月 07, 2026
期间报告EPS ActualEPS 预期惊喜
2026年6月30日 $-0.43 $-0.01 -3061.8%
2026年3月31日 $-0.24 $-0.14 -68.1%
2025年12月31日 $-0.41 $-0.20 -101.0%
2025年9月30日 $0.00 $-0.23 100.0%
2025年6月30日 $-13.00 $-0.24 -5362.2%
2025年3月31日 $-0.96 $-0.41 -135.3%

完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表

15
损益表 18
指标 趋势 2026202520242023202220212020201920182017
Revenue $915M$821M$789M$627M$628M$513M$210M$167M$43M$21M
Cost of Revenue $655M$581M$566M$480M$512M$390M$186M$190M$29M$9M
Gross Profit $260M$241M$223M$147M$117M$123M$25M$-23M$14M$11M
R&D Expense $361.0K$284.0K$635.0K$682.0K$2M$830.0K$4M$9M$6M$3M
SG&A Expense $204M$167M$167M$165M$163M$112M$86M$111M$49M$7M
Operating Expenses $323M$2.52B$398M$1.52B$727M$255M····
Operating Income $-63M$-2.28B$-175M$-1.37B$-610M$-132M$-201M$-304M$-58M$-7M
Interest Expense $30M$41M$49M$47M$40M$31M····
Interest Income $6M$11M$13M$33M$12M$3M$798.0K$149.0K··
Other Non-op $-1M$10M$-38M$-67M$198M$-185M$-10M$3M$2M$12.0K
Pretax Income $-88M$-2.30B$-249M$-1.45B$-441M$-345M$-277M$-330M$-72M$-8M
Income Tax $17M$-121M$-27M$-7M$-7M$-9M$-6M$-8M$-4M·
Net Income $-121M$-2.19B$-245M$-1.45B$-477M$-367M$-271M$-321M$-68M$-8M
EPS (Basic) $-1.09$-24.56$-3.30$-2.35$-0.99$-1.36····
EPS (Diluted) $-1.09$-24.56$-3.30$-2.35$-0.99$-1.36····
Shares (Basic) 111,832,37589,032,60274,264,948617,982,589481,219,130269,549,852····
Shares (Diluted) 111,832,37589,032,60274,264,948617,982,589481,219,130269,549,852····
EBITDA $-63M$-2.28B$-175M$-1.37B·$-64M··$-54M·
资产负债表 32
指标 趋势 2026202520242023202220212020201920182017
Cash & Equivalents $226M$222M$228M$207M$416M$488M$190M$97M$487M$2M
Short-term Investments $5M$35M$32M$242M$0···$30M·
Receivables $189M$121M$102M$86M$95M$87M$29M$36M$17M$983.0K
Inventory $301M$271M$252M$201M$246M$256M$94M$88M$16M$7M
Prepaid Expense $65M$34M$31M$38M$47M$49M$35M$38M$4M$545.0K
Other Current Assets ·····$9M····
Current Assets $792M$689M$678M$773M$804M$884M$347M$259M$554M$12M
PP&E (Net) $680M$568M$558M$430M$587M$651M$200M$184M$80M$40M
PP&E (Gross) ···$576M$755M$728M$227M$201M$88M$45M
Accum. Depreciation ····$167M$77M$28M$17M$8M$5M
Goodwill $752M$752M$2.01B$2.01B$2.64B$2.83B$167M$163M··
Intangibles $43M$21M$915M$974M$1.28B$1.61B$186M$229M$4M$934.0K
Other Non-current Assets $11M$11M$5M$222.0K$314.0K$8M$4M$8M··
Total Assets $2.33B$2.07B$4.22B$4.31B$5.45B$6.03B$946M$896M$657M$54M
Accounts Payable $115M$107M$105M$71M$69M$58M$18M$39M$11M$6M
Accrued Liabilities $136M$103M$92M$78M$57M$113M····
Short-term Debt $9M$7M$18M$23M$18M$9M····
Current Liabilities $358M$280M$299M$433M$280M$401M$181M$92M$26M$50M
Capital Leases $38M$21M$16M$8M$11M$18M$15M$15M$8M$9M
Deferred Tax $12M$4M$131M$167M$197M$266M$49M$53M$4M·
Other Non-current Liabilities $4M$855.0K$90.0K$215.0K$191.0K$4M$5M$6M··
Total Liabilities $733M$585M$778M$977M$1.01B$1.56B$572M$611M$459M$59M
Long-term Debt ····$186M$204M···$9M
Total Debt $9M$7M$18M$23M·$213M····
Common Stock $132.0K$106.0K$83.0K$66.0K$53.0K$46.0K····
Paid-in Capital ······$1.10B$706M$302M$32M
Retained Earnings $-4.97B$-4.85B$-2.66B$-2.42B$-963M$-486M$-730M$-430M$-108M$-40M
Treasury Stock $0$0$0·······
AOCI $-44M$-43M$-43M$-47M$-21M$153M$8M$10M$4M$4M
Stockholders' Equity $1.61B$1.51B$3.44B$3.32B$4.40B$4.46B$374M$285M$198M$-5M
Liabilities + Equity $2.33B$2.07B$4.22B$4.31B$5.45B$6.03B$946M$896M$657M$54M
Shares Outstanding 131,683,075106,067,875831,925,373656,655,455532,674,887446,440,641···0
现金流 16
指标 趋势 2026202520242023202220212020201920182017
D&A ····$155M$68M$19M$16M$4M$2M
Stock-based Comp $46M$24M$32M$40M$36M$17M$30M$32M$21M$139.0K
Deferred Tax $8M$-126M$-39M$-34M$-31M$-25M$-5M$-9M$-4M·
Amort. of Intangibles ·····$27M$11M$10M$374.0K$549.0K
Restructuring $13M$34M$16M$9M$795.0K$0····
Other Non-cash ·····$211M··$1M·
Operating Cash Flow $-69M$-95M$-31M$8M$-177M$-45M$-129M$-258M$-46M$-6M
CapEx ·$33M$29M$21M$34M$39M$45M$74M$50M$11M
Investing Cash Flow $-56M$-47M$128M$-285M$-22M$46M$-42M$-253M$-99M$-12M
Stock Issued $158M$161M$9M$130M$263M$103M$85M···
Net Stock Activity $158M$161M$9M$130M·$103M····
Financing Cash Flow $131M$134M$-75M$70M$128M$124M$265M$115M$631M$12M
Net Change in Cash $8M$-7M$22M$-209M$-73M$128M$93M$-390M$485M$-5M
Taxes Paid $235.0K····$6M····
Free Cash Flow ·$-128M$-60M$-13M·$-84M··$-96M·
Levered FCF ·$-167M$-104M$-59M······
盈利能力 8
指标 趋势 2026202520242023202220212020201920182017
Gross Margin 28.4%29.3%28.3%23.4%·24.0%··33.1%·
Operating Margin -6.9%-277.9%-22.1%-218.4%·-25.8%··-133.7%·
Net Margin -13.3%-266.2%-31.1%-231.6%·-71.6%··-157.0%·
Pretax Margin -9.6%-280.3%-31.6%-231.2%·-67.2%··-167.3%·
EBITDA Margin -6.9%-277.9%-22.1%-218.4%·-12.5%··-125.4%·
ROA -5.5%-79.8%-5.8%-29.8%·-10.5%··-19.1%·
ROE -7.8%-103.1%-7.1%-37.7%·-15.2%··-35.1%·
ROIC -4.6%-142.4%-4.5%-40.8%·-2.8%··-29.2%·
流动性与偿付能力 5
指标 趋势 2026202520242023202220212020201920182017
Current Ratio 2.22.52.31.8·2.2··21.4·
Quick Ratio 1.21.31.21.2·1.4··20.6·
Debt / Equity 0.00.00.00.0·0.0····
LT Debt / Equity ·····0.0····
Interest Coverage -2.1-55.2-3.5-29.4······
效率 3
指标 趋势 2026202520242023202220212020201920182017
Asset Turnover 0.40.30.20.1·0.1··0.1·
Inventory Turnover 2.32.22.22.2·2.2··2.4·
Receivables Turnover 5.97.37.86.9·8.8··4.9·
每股 5
指标 趋势 2026202520242023202220212020201920182017
Book Value / Share $12.26$1.43$4.14$5.05·$9.99····
Revenue / Share $8.19$0.92$1.06$1.01·$1.90····
Cash Flow / Share $-0.62$-0.11$-0.04$0.01·$-0.17····
Cash / Share $1.72$0.21$0.27$0.31·$1.09····
EPS (TTM) $-1.09$-2.46$-0.33$-2.35$-0.99$-1.36$-0.94···
增长率 3
指标 趋势 2026202520242023202220212020201920182017
Revenue YoY 11.5%4.1%25.8%-0.20%22.5%26.6%····
Revenue CAGR 3Y 13.4%9.3%15.4%15.7%······
Revenue CAGR 5Y 12.3%15.2%········
估值 (TTM) 14
指标 趋势 2026202520242023202220212020201920182017
Revenue TTM $915M$821M$789M$627M$628M$513M$210M$167M$43M·
Net Income TTM $-121M$-2.19B$-245M$-1.45B$-477M$-367M$-271M$-321M$-68M·
Market Cap $726M$456M$1.50B$1.10B·$7.44B····
Enterprise Value $503M$207M$1.25B$671M·$7.17B····
P/E -5.1-0.2-5.5-0.7-4.5-12.3-8.8···
P/S 0.80.61.91.7·14.5····
P/B 0.40.30.40.3·1.7····
P / Tangible Book 0.90.62.93.35.0365.6····
P / Cash Flow -10.5-4.8-48.5138.7·-166.4····
P / FCF ·-3.6-24.9-85.0·-89.0····
EV / EBITDA -8.0-0.1-7.2-0.5·-111.4····
EV / FCF ·-1.6-20.9-52.1·-85.7····
EV / Revenue 0.50.31.61.1·14.0····
Earnings Yield -19.8%-572.1%-18.3%-140.7%-22.1%-8.2%-11.4%···

最近期在左侧 · 空值显示为 ·

财务报表 损益表、资产负债表、现金流量表 — 年度,近5年

16
指标 2026-05-312025-12-312025-05-312024-12-312024-05-31
收入 $915M · $821M · $789M
毛利率 % 28.4% · 29.3% · 28.3%
营业利润率 % -6.9% · -277.9% · -22.1%
净收入 $-121M · $-2.19B · $-245M
稀释后每股收益 (EPS) $-1.09 · $-24.56 · $-3.30

机构持有人 (13F) 270 家申报者 · $126.8M 总计 · 截至 2026年6月30日

17

在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸;单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存,而非方向性判断。

持有人 270
持有价值 $126.8M
新仓位 45
已退出持仓 20
机构活动 — Q2 2026 与上一季度对比
新仓位 已退出持仓 增加 减少 净股数变动
45 (0 与上一季度对比) 20 (-16 与上一季度对比) 64 (+9 与上一季度对比) 60 (+8 与上一季度对比) +2.7M

与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天,外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过,优先显示最近一个已完整报告的季度对。

机构 价值 股份 % 已追踪的13F 类型
Toroso Investments, LLC $20948841 2319916 16.53% 股份
SUSQUEHANNA INTERNATIONAL GROUP, LLP $17994124 4007600 14.19% 买入期权
SUSQUEHANNA INTERNATIONAL GROUP, LLP $14724057 3279300 11.62% 卖出期权
SUSQUEHANNA INTERNATIONAL GROUP, LLP $4587779 1021777 3.62% 股份
MORGAN STANLEY $4468200 995145 3.52% 股份
CITADEL ADVISORS LLC $3980385 886500 3.14% 买入期权
VANGUARD GROUP INC $3945672 436921 3.11% 股份
CITADEL ADVISORS LLC $3897980 868147 3.07% 股份
CITADEL ADVISORS LLC $3551186 790910 2.80% 卖出期权
Point72 Asset Management, L.P. $2911884 648506 2.30% 股份
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. $2903961 646762 2.29% 股份
AQR CAPITAL MANAGEMENT LLC $2301570 512599 1.82% 股份
Walleye Capital LLC $2103565 468500 1.66% 买入期权
BlackRock, Inc. $2072834 461656 1.64% 股份
UBS Group AG $2039286 454184 1.61% 股份
LAZARD ASSET MANAGEMENT LLC $1772270 394715 1.40% 股份
STATE STREET CORP $1724712 384123 1.36% 股份
VANGUARD PORTFOLIO MANAGEMENT LLC $1565569 348679 1.24% 股份
Walleye Trading LLC $1430065 318500 1.13% 买入期权
STIFEL FINANCIAL CORP $1305987 290864 1.03% 股份
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $1270288 196335 1.00% 股份
Walleye Trading LLC $1233403 274700 0.97% 卖出期权
WOLVERINE TRADING, LLC $1104820 597200 0.87% 买入期权
XTX Topco Ltd $1100589 245120 0.87% 股份
Swiss National Bank $1049775 233803 0.83% 股份
GOLDMAN SACHS GROUP INC $935150 208274 0.74% 股份
JANE STREET GROUP, LLC $914388 203650 0.72% 买入期权
WOLVERINE TRADING, LLC $750545 405700 0.59% 卖出期权
Headlands Technologies LLC $721386 160665 0.57% 股份
Parallax Volatility Advisers, L.P. $673500 150000 0.53% 买入期权
D. E. Shaw & Co., Inc. $666362 148383 0.53% 股份
Walleye Capital LLC $638478 142200 0.50% 卖出期权
TWO SIGMA INVESTMENTS, LP $610056 135870 0.48% 股份
JANE STREET GROUP, LLC $551642 122860 0.44% 股份
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM $546518 121719 0.43% 股份
NORTHERN TRUST CORP $496886 110665 0.39% 股份
SIG North Trading, ULC $462560 103020 0.36% 买入期权
SIG North Trading, ULC $450827 100407 0.36% 股份
Lighthouse Investment Partners, LLC $436783 97279 0.34% 股份
Cetera Investment Advisers $421589 93895 0.33% 股份
WOLVERINE TRADING, LLC $402190 217400 0.32% 股份
GEODE CAPITAL MANAGEMENT, LLC $388061 86428 0.31% 股份
Legal & General Group Plc $381295 84921 0.30% 股份
AdvisorShares Investments LLC $342421 76263 0.27% 股份
VANGUARD ASSET MANAGEMENT, Ltd $326284 72669 0.26% 股份
TORONTO DOMINION BANK $298732 66474 0.24% 股份
ALLSTATE CORP $294706 65636 0.23% 股份
Walleye Trading LLC $283624 63168 0.22% 股份
FOX RUN MANAGEMENT, L.L.C. $283373 63112 0.22% 股份
Engineers Gate Manager LP $273167 60839 0.22% 股份

显示全部 270 个机构持有人 →

激进投资者及 5%+ 股东 5 持仓

18

提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权,意图影响发行人(激进股东持股、董事会活动、并购)。每一行显示该申报人持仓的最新已知状态。

申报人 已申报 持股 状态 目的 申报
Tilray Brands, Inc. 2022年7月22日 · 初始申报 被动投资 SEC
Tilray, Inc. 2021年12月17日 · 初始申报 被动投资 SEC
Brendan Kennedy ×6 申报 2021年5月25日 · 初始申报 · SEC
Michael Blue 2021年2月16日 · 初始申报 · SEC
Christian Groh 2021年2月16日 · 初始申报 · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

公司内部人士 25 位内幕人士 · 11 位高管 · 15 位董事

19
内部人士 角色 上次活动 持股数量 买入 12个月 卖出 12个月 净额 12个月
Irwin D Simon President and CEO 2026年8月26日 M 1309031 0 0 $0
Carl A Merton Chief Financial Officer 2026年8月26日 M 215556 1 0 $46200
Michael C. Kruteck Chief Financial Officer 2021年4月30日 M 125156 0 0 $0
Mark Castaneda CFO, Secretary, Treasurer 2019年7月18日 M 129505 0 0 $0
Kathryn P Dickson President- Manitoba Harvest 2020年3月5日 A · 0 0 $0
Jon Edward Levin Chief Operating Officer 2021年4月30日 M 119857 0 0 $0
Denise M Faltischek Chief Strategy Officer 2026年8月26日 M 225047 1 0 $11950
Mitchell Gendel Global General Counsel 2026年8月26日 M 200225 1 0 $11075
James R. Meiers Chief Operations Officer 2022年6月1日 M 85631 0 0 $0
Andrew Pucher Chief Corporate Dev Officer 2021年3月18日 M 31402 0 0 $0
Edward Wood Pastorius JR Chief Revenue Officer 2020年10月1日 M 116180 0 0 $0
David G. Hopkinson 董事 2026年7月30日 A 43104 0 1 $-232879
Thomas P. Looney 董事 2026年7月30日 A 397520 0 0 $0
Johann Michael Herhalt 董事 2026年7月30日 A 195561 0 0 $0
Renah Persofsky 董事 2026年7月29日 A 155357 0 0 $0
Steven Michael Cohen 董事 2026年7月29日 A 55542 0 0 $0
David F Clanachan 董事 2026年7月29日 A 192511 0 0 $0
Jodi L. Butts 董事 2024年7月30日 A 112502 0 0 $0
Brendan Kennedy 董事 2022年11月7日 S 6224196 0 0 $0
Walter E Robb IV 董事 2022年7月26日 A 4190 0 0 $0
Michael Auerbach 董事 2021年4月30日 M 333665 0 0 $0
Rebekah Dopp 董事 2021年4月30日 M 59993 0 0 $0
Soren Schroder 董事 2021年4月30日 M 35817 0 0 $0
Christine St.Clare 董事 2021年4月30日 M 58143 0 0 $0
Maryscott Greenwood 董事 2020年9月30日 A 47087 0 0 $0

来自SEC表格3/4/5申报的内部人士;净额=仅公开市场买卖

ETF持仓 由 10 只交易所交易基金持有

20

权重仅反映直接股权持仓(N-PORT);杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。

基金 权重 单位 截至 来源
PDN · Invesco Exchange-Traded Fund Trus... 0.04% 33059 SH 2026年10月1日 每日
VHT · VANGUARD WORLD FUND 0.01% 348679 SH 2026年8月19日 每日
FHLC · FIDELITY COVINGTON TRUST 0.01% 57332 NS 2026年7月31日 N-PORT
DFIS · Dimensional ETF Trust 0.01% 79064 NS 2026年7月31日 N-PORT
WSML · iShares Trust 0.00% 6269 SH 2026年9月10日 每日
DFAI · Dimensional ETF Trust 0.00% 72416 NS 2026年7月31日 N-PORT
DFIC · Dimensional ETF Trust 0.00% 34842 NS 2026年7月31日 N-PORT
ISCB · iShares Trust · 5304 SH 2026年9月11日 每日
ISCV · iShares Trust · 28658 SH 2026年9月11日 每日
SMLF · iShares Trust · 88214 SH 2026年9月11日 每日

TLRY 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间

21
评级 · 17 位分析师 买入
中位数目标 $5.50 +52.4%
3 17.6% 强烈买入
5 29.4% 买入
9 52.9% 持有
0 0.0% 卖出
0 0.0% 强烈卖出

12个月价格目标

8 位分析师 · 2026-10-01

平均目标 $7.34 +103.4%

← 低于所有目标 当前价格 $3.61
最低$4.25 平均值$7.34 最高$17.00

同行比较(GICS 子行业) 关键指标与行业同行对比

22

财年依据,价格截至各公司上一个财年末收盘价。

股票代码 市值 P/E 营收同比增长 净利润率 ROE 毛利率
TLRY $726M -5.1 11.5% -13.3% -7.8% 28.4%
SNDL · -27.7 · -1.7% -1.4% 27.3%

最新新闻 提及该公司的近期头条新闻

23

我的指标 您的个人关注列表 — 来自完整基本面的选定行

26

选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。

您的选择已保存,并会跟随您浏览所有股票。

来源:SEC 10-K 于 七月 28, 2026 申报